700263 | Glycoursodeoxycholic acid
5β-cholanic acid-3α,7β-diol N-(carboxymethyl)-amide
Glycoursodeoxycholic acid
5β-cholanic acid-3α,7β-diol N-(carboxymethyl)-amide
Glycoursodeoxycholic Acid (GUDCA), also referred to as Ursodeoxycholyl Glycine or Glycine Ursodeoxycholic Acid is an acyl glycine and a bile acid (BA) - glycine conjugate, and has a role as a human blood serum metabolite.
The compound is a secondary BA, formed by the action of enzymes belonging to the microbiota in the colonic environment. In liver hepatocytes, both primary and secondary BAs go through amino acid conjugation with the amino acids glycine or taurine at the C-24 carboxylic acid on the side chain, thus most BAs in the bile duct exists exactly in a glycine conjugated form.
This is how Glycoursodeoxycholic Acid is derived from the secondary BA ursodeoxycholic acid (ursodiol). Ursodiol, on the other hand, is an epimer of chenodeoxycholic acid and serves as a detergent widely used in the treatment of hepatobiliary disorders associated with gallstone formation, cystic fibrosis, etc. as a cholagogue and choleretic.
On the subject of Glycoursodeoxycholic Acid, it’s a compound with diverse roles and functions.
GUDCA has been known to show potent antioxidant effects in Barrett’s esophagus cells and primary cultured rat neurons. Its mechanism of action is reducing levels of inflammatory cytokines and preventing cell damage and death by unconjugated bilirubin. Glycoursodeoxycholic Acid’s antioxidative effects also come from its ability to inhibit UCB-induced cytochrome C oxidase and also prevent metabolic alterations and cell demise.
It has been proven that oral administration of Glycoursodeoxycholic Acid in a mouse model of colitis decreases the severity of symptoms and increases the amount of the bacterial microorganism A. muciniphila, which is decreased in this and similar conditions.
Studies also discovered that Glycoursodeoxycholic Acid serves as a potent neuroprotective agent in neurodegenerative models and diseases. The BA displays restorative and protective properties against unconjugated bilirubin-induced blood-brain barrier disruption and damage in human brain microvascular endothelial cells.
Alongside the improvement of these metabolic disorders, Glycoursodeoxycholic Acid is also associated with the inhibition of atherosclerosis development. This effect of GUDCA probably comes from its ability to inhibit foam cell formation, maintenance of cholesterol homeostasis, and balance the gut microbiota.
Avanti Research manufactures high-quality Glycoursodeoxycholic Acid for a broad range of analyses and research.
C26H43NO5
C 69.45%, H 9.64%, N 3.12%, O 17.79%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by Bioz- Certificate of Analysis (Lot No. 700263P-10MG-A-010 and 6836PIA010)
- Certificate of Analysis (Lot No. 700263P-10MG-B-010 and 6836PIB010)
